{
    "id": 11335,
    "fullName": "EGFR L747_T751delinsP",
    "impact": "indel",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR L747_T751delinsP results in the deletion of five amino acids in the protein kinase domain of the Egfr protein from amino acids 747 to 751, combined with the insertion of a proline (P) at the same site (UniProt.org). L747_T751delinsP has not been biochemically characterized, but is predicted to result in a gain of function based on the effect of other EGFR exon 19 deletion and deletion-insertion mutations (PMID: 19147750, PMID: 22190593, PMID: 23387505).",
            "references": [
                {
                    "id": 441,
                    "pubMedId": 23387505,
                    "title": "Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23387505"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 439,
                    "pubMedId": 22190593,
                    "title": "EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22190593"
                },
                {
                    "id": 1890,
                    "pubMedId": 19147750,
                    "title": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19147750"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "L747_T751delinsP",
    "createDate": "09/03/2015",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": {
        "id": 135755,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55174776_55174790delinsCCT",
        "cDna": "c.2239_2253delinsCCT",
        "protein": "p.L747_T751delinsP",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3049,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, 3 patients with lung adenocarcinoma harboring EGFR L747_T751delinsP demonstrated partial responses when treated with Iressa (gefitinib) therapy (PMID: 18981003).",
            "molecularProfile": {
                "id": 11383,
                "profileName": "EGFR L747_T751delinsP"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12548,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were resistant to treatment with Erbitux (cetuximab) in culture (PMID: 29141884).",
            "molecularProfile": {
                "id": 11383,
                "profileName": "EGFR L747_T751delinsP"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12546,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were sensitive to treatment with Gilotrif (afatinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 11383,
                "profileName": "EGFR L747_T751delinsP"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12543,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were sensitive to treatment with Iressa (gefitinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 11383,
                "profileName": "EGFR L747_T751delinsP"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12547,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were sensitive to treatment with Rociletinib (CO-1686) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 11383,
                "profileName": "EGFR L747_T751delinsP"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12544,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L747_T751delinsP were sensitive to treatment with Tarceva (erlotinib) in culture, demonstrating reduced cell viability (PMID: 29141884).",
            "molecularProfile": {
                "id": 11383,
                "profileName": "EGFR L747_T751delinsP"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10358,
                    "pubMedId": 29141884,
                    "title": "A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29141884"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3053,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP, who was found to have acquired an EGFR T790M mutation upon disease progression on Iressa (gefitinib), had rapid disease progress in response Tarceva (erlotinib) therapy (PMID: 18981003).",
            "molecularProfile": {
                "id": 11384,
                "profileName": "EGFR L747_T751delinsP EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3051,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP that developed resistance to Iressa (gefitinib) was found to have acquired an EGFR T790M mutation (PMID: 18981003).",
            "molecularProfile": {
                "id": 11384,
                "profileName": "EGFR L747_T751delinsP EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15117,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, AGK-BRAF was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR L747_T751delinsP, whose disease progressed after initial response to Tarceva (erlotinib) followed by Tagrisso (osimertinib) (PMID: 29883838).",
            "molecularProfile": {
                "id": 30761,
                "profileName": "AGK - BRAF EGFR L747_T751delinsP"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15122,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EML4-ALK was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR L747_T751delinsP, whose disease progressed after initial response to Gilotrif (afatinib) (PMID: 29883838).",
            "molecularProfile": {
                "id": 30767,
                "profileName": "EML4 - ALK EGFR L747_T751delinsP"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11383,
            "profileName": "EGFR L747_T751delinsP",
            "profileTreatmentApproaches": [
                {
                    "id": 6431,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR L747_T751delinsP"
                },
                {
                    "id": 6432,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR L747_T751delinsP"
                },
                {
                    "id": 6434,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR L747_T751delinsP"
                },
                {
                    "id": 6433,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR L747_T751delinsP"
                },
                {
                    "id": 6435,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR L747_T751delinsP"
                }
            ]
        },
        {
            "id": 11384,
            "profileName": "EGFR L747_T751delinsP EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30761,
            "profileName": "AGK - BRAF EGFR L747_T751delinsP",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30767,
            "profileName": "EML4 - ALK EGFR L747_T751delinsP",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135755,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55174776_55174790delinsCCT",
            "cDna": "c.2239_2253delinsCCT",
            "protein": "p.L747_T751delinsP",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}